26
Participants
Start Date
March 29, 2019
Primary Completion Date
April 20, 2022
Study Completion Date
April 20, 2022
Pelareorep
4.5 × 10e10 TCID50 administered intravenously on Days 1, 2, 8 \& 9
Letrozole
Oral dose of 2.5 mg/day starting on Day 3 for 13 days
Atezolizumab
1200 mg administered intravenously on Day 3
Trastuzumab
8mg/kg administered intravenously or 600mg subcutaneously on Day 3
ICO Badalona, Badalona
Hospital Clínic de Barcelona, Barcelona
Hospital Quirón Dexeus, Barcelona
Hospital Moisés Broggi, Esplugues de Llobregat
Hospital Fuenlabrada, Madrid
Hospital La Paz, Madrid
Hospital Puerta de Hierro de Majadahonda, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario Fundación Jiménez Díaz, Madrid
Hospital Clínico Universitario Virgen Arrixaca, Murcia
Hospital Universitario Virgen Macarena, Seville
Hospital Clínico Universitario de Valencia, Valencia
Instituto Valenciano de Oncología, Valencia
Hospital Clínico Lozano Blesa, Zaragoza
Lead Sponsor
SOLTI Breast Cancer Research Group
OTHER
Oncolytics Biotech
INDUSTRY